Basilea Pharmaceutica AG is a Swiss-based pharmaceutical company with an ESG score of 25.5, putting it at a medium risk level. Specializing in meeting the needs of patients with severe bacterial and fungal infections, Basilea Pharmaceutica AG is dedicated to discovering, developing, and commercializing drugs. With operating subsidiaries in the United Kingdom and Germany, the company derives its revenue from various countries including Japan, USA, Sweden, and more.